Log in

NASDAQ:SLNOSoleno Therapeutics Stock Price, Forecast & News

Today's Range N/A
50-Day Range
MA: $1.91
52-Week Range N/A
Volume307,438 shs
Average Volume514,447 shs
Market Capitalization$80.03 million
P/E RatioN/A
Dividend YieldN/A
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More
Soleno Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.39 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:SLNO



Sales & Book Value

Annual SalesN/A
Book Value$0.33 per share


Net Income$-30,770,000.00


Market Cap$80.03 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Soleno Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Soleno Therapeutics

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Soleno Therapeutics

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its earnings results on Monday, August, 10th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05.
View Soleno Therapeutics' earnings history

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics shares reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for SLNO?

3 Wall Street analysts have issued 12 month target prices for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Soleno Therapeutics' stock price to reach $9.33 in the next twelve months.
View analysts' price targets for Soleno Therapeutics

Has Soleno Therapeutics been receiving favorable news coverage?

Media headlines about SLNO stock have trended positive this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Soleno Therapeutics earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Soleno Therapeutics

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 239,200 shares, a drop of 38.2% from the December 31st total of 387,000 shares. Based on an average daily trading volume, of 287,900 shares, the short-interest ratio is currently 0.8 days. Currently, 0.8% of the company's shares are sold short.
View Soleno Therapeutics' Short Interest

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Opko Health (OPK), Dynavax Technologies (DVAX), Miragen Therapeutics (MGEN) and Vaxart (VXRT).

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:
  • Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
  • Mr. David D. O'Toole, Consultant (Age 60)
  • Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.15%), New York State Common Retirement Fund (0.12%), State Board of Administration of Florida Retirement System (0.05%) and UBS Group AG (0.04%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc.
View institutional ownership trends for Soleno Therapeutics

Which institutional investors are buying Soleno Therapeutics stock?

SLNO stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, and UBS Group AG. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler, and Larry N Feinberg.
View insider buying and selling activity for Soleno Therapeutics

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $0.00. The company earns $-30,770,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.